NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the presence of t(9;22) chromosomal translocation that results in BCR-ABL fusion gene. ABL tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, and dasatinib, are currently the front-line treatment options for C...

Full description

Bibliographic Details
Main Authors:	Ming-Chin Chang, Hung-I Cheng, Kate Hsu, Yen-Ning Hsu, Chen-Wei Kao, Yi-Fang Chang, Ken-Hong Lim, Caleb Gonshen Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-01-01
Series:	Frontiers in Immunology
Subjects:	CML BCR-ABL major molecular response (MMR) deep molecular response (DMR) natural killer cell NKG2A
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2018.03152/full

Similar Items

A study to determine the clinical, hematological, cytogenetic, and molecular profile in CML patient in and around Eastern UP, India
by: Sandip Kumar, et al.
Published: (2019-01-01)

Emergence role of nucleated red blood cells in molecular response evaluation for chronic myeloid leukemia
by: Phan TT, et al.
Published: (2019-09-01)

Influence of late treatment on how chronic myeloid leukemia responds to imatinib
by: Ana Carolina Costa Scerni, et al.
Published: (2009-01-01)

Complete Molecular Response due to nilotinib as III line treatment in a patient with CML and F317L point mutation of the Bcr-Abl kinase domain
by: Maria Iovine, et al.
Published: (2015-10-01)

Änderung der Stoffwechselaktivität von BaF3-Zellen durch die Expression von BCR/ABL
by: Engelmann, Ines
Published: (2015)

Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: M Yaghmaie, et al.
Published: (2005-09-01)

Frequency of BCR-ABL Fusion Transcript in Iranian Patients with Chronic Myeloid Leukemia
by: Yaghmaie M., et al.
Published: (2005-09-01)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
by: Anna Kreutzman, et al.
Published: (2019-09-01)

DNA-based vaccines against cancer
by: Chen, Caleb Gonshen
Published: (2004)

Methylenetetrahydrofolate Reductase Gene C677T and A1298C Polymorphic Sequence Variations Influences the Susceptibility to Chronic Myeloid Leukemia in Kashmiri Population
by: Shahid M. Baba, et al.
Published: (2019-07-01)

Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients
by: Mahmood S. Khazaal, et al.
Published: (2019-08-01)

Monitoração molecular da Leucemia Mielóide Crônica na era do imatinibe Molecular monitoring of Chronic Myeloid Leukemia in the imatinib era
by: Israel Bendit
Published: (2008-04-01)

GSK-3α Inhibition in Drug-Resistant CML Cells Promotes Susceptibility to NK Cell-Mediated Lysis in an NKG2D- and NKp30-Dependent Manner
by: Nayoung Kim, et al.
Published: (2021-04-01)

Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR
by: Aleksandar Jovanovski, et al.
Published: (2020-11-01)

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors
by: Michael G. Martin, et al.
Published: (2011-12-01)

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
by: Michele Massimino, et al.
Published: (2018-02-01)

Diagnostic and therapeutic implications of genetic heterogeneity in myeloid neoplasms uncovered by comprehensive mutational analysis
by: Sarah M. Choi, et al.
Published: (2017-01-01)

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy
by: Huang X, et al.
Published: (2019-06-01)

<i>ABL</i> Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo
by: Shu-Huey Chen, et al.
Published: (2020-05-01)

The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach
by: Ting-Ting Huang, et al.
Published: (2021-03-01)

AVALIAÇÃO DE DOENÇA RESIDUAL MÍNIMA EM PACIENTES COM LEUCEMIA MIELÓIDE CRÔNICA.
by: Leal, Caio Bruno Quinta de Souza
Published: (2016)

Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition
by: Miriam Pons, et al.
Published: (2021-07-01)

Fusion gene bcr-abl: From etiopathogenesis to the management of chronic myeloid leukemia
by: Tri Agusti Sholikah
Published: (2017-04-01)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01)

Molecular diagnosis of bcr-abl fusion gene in CML patients using Monoplex-Two Steps- Reveres Transcriptase–Polymerase Chain
by: Maysaa A. Dhahii
Published: (2010-04-01)

Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells
by: Xu, Yan
Published: (2018)

Novel therapies for treatment of Ph+ acute leukemias
by: Walker, Christopher James
Published: (2013)

NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE
by: Gianfranco Catalano, et al.
Published: (2020-10-01)

A novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case
by: Fen Zhou, et al.
Published: (2017-05-01)

Effect of Plumbagin on growth inhibition and apoptosis of imatinib-resistant chronic myeloid leukemia
by: Bui Thi Kim Ly, et al.
Published: (2017-08-01)

Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
by: Zhou L, et al.
Published: (2019-12-01)

Prognostic Factors for 12 Month Major Molecular Response for Patients with Chronic Myeloid Leukemia
by: Höijer, Jonas
Published: (2013)

Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy
by: Elena Vuelta, et al.
Published: (2021-02-01)

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
by: Flis S, et al.
Published: (2019-03-01)

<i>Sphagneticola Trilobata</i> (L.) Pruski (Asteraceae) Methanol Extract Induces Apoptosis in Leukemia Cells through Suppression of BCR/ABL
by: Hoang Thanh Chi, et al.
Published: (2021-05-01)

Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia
by: Laura Kearney, et al.
Published: (2020-01-01)

Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib
by: Giuseppe Pietrantuono
Published: (2015-10-01)

Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
by: Mousa Vatanmakanian, et al.
Published: (2019-04-01)

The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia
by: Sara Galimberti, et al.
Published: (2018-12-01)

Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches
by: Sandra Preuner, et al.
Published: (2016-04-01)